Akebia Therapeutics, Inc. (NASDAQ:AKBA)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Wednesday. They currently have a $24.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 68.54% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. Mizuho initiated coverage on Akebia Therapeutics in a research note on Wednesday, October 4th. They set a “buy” rating and a $24.00 target price for the company. Zacks Investment Research upgraded Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Monday, August 14th. Royal Bank Of Canada reiterated a “hold” rating and issued a $17.00 price objective on shares of Akebia Therapeutics in a research note on Thursday, November 2nd. ValuEngine upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, BidaskClub upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $20.75.

Shares of Akebia Therapeutics (AKBA) opened at $14.24 on Wednesday. Akebia Therapeutics has a 52 week low of $7.78 and a 52 week high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.07. The firm had revenue of $41.28 million during the quarter, compared to analysts’ expectations of $34.00 million. Akebia Therapeutics had a negative return on equity of 198.85% and a negative net margin of 137.80%. equities research analysts predict that Akebia Therapeutics will post -2.74 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Reaffirms “Buy” Rating for Akebia Therapeutics, Inc. (AKBA)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/hc-wainwright-reaffirms-buy-rating-for-akebia-therapeutics-inc-akba/1704256.html.

In other news, SVP Michel Dahan sold 1,398 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $19.64, for a total value of $27,456.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 7,586 shares of company stock worth $147,289. Corporate insiders own 8.67% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Akebia Therapeutics in the second quarter valued at approximately $132,000. Macquarie Group Ltd. acquired a new position in shares of Akebia Therapeutics in the third quarter valued at approximately $183,000. Legal & General Group Plc increased its holdings in shares of Akebia Therapeutics by 8.0% in the second quarter. Legal & General Group Plc now owns 9,672 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 714 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in shares of Akebia Therapeutics in the third quarter valued at approximately $200,000. Finally, Creative Planning increased its holdings in shares of Akebia Therapeutics by 2.9% in the second quarter. Creative Planning now owns 10,650 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 300 shares during the period. 59.27% of the stock is currently owned by institutional investors and hedge funds.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.